Safety and efficacy of topical vs intracanalicular corticosteroids for the prevention of postoperative inflammation after cataract surgery
Open Access
- 9 May 2022
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cataract & Refractive Surgery
- Vol. 48 (11), 1242-1247
- https://doi.org/10.1097/j.jcrs.0000000000000963
Abstract
Purpose: To compare the safety and efficacy of topical prednisolone and intra-canalicular dexamethasone ophthalmic insert for the prevention of post-operative inflammation after cataract surgery. Setting: Penn State College of Medicine, Hershey, PA. Design: Retrospective consecutive case series. Methods: Patients scheduled for elective phacoemulsification cataract surgery with a plan to receive inflammation prophylaxis with topical prednisolone (prednisolone acetate 1mg/1mL) between January 2018 and November 2019 or intracanalicular dexamethasone (Dextenza, 0.4mg, Ocular Therapeutix) between December 2019 and March 2021 were screened. Patients were seen 1 day, 1 week, and 4-16 weeks postoperatively. Medical records were also reviewed for any urgent messages between visits. Primary endpoints were proportion of eyes with 1) breakthrough inflammation requiring escalation of anti-inflammatory therapy and 2) intraocular pressure (IOP) increase ≥ 10mmHg at 4-16 weeks follow-up. Secondary endpoints included incidence of intra-operative complications, cystoid macular edema, and infectious sequelae. Results: Three-hundred and fifty-eight patient charts (358 eyes) were screened. Of these, 262 eyes of 262 patients met criteria for inclusion in the study; 131 eyes received topical drops and 131 eyes received the intracanalicular insert. Amongst eyes that completed follow-up, 9 eyes (6.9%) in the drops group and 12 eyes (9.2%) in the insert group experienced breakthrough inflammation necessitating treatment (P = .50). Two eyes in the drops group and 1 eye in the insert group had elevated IOP. Conclusions: Postoperative inflammation prophylaxis with the intracanalicular insert may be associated with similar rates of breakthrough inflammation and IOP elevation as topical drops.Keywords
This publication has 24 references indexed in Scilit:
- Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgeryCurrent Opinion in Opthalmology, 2017
- Evaluation of eyedrop administration by inexperienced patients after cataract surgeryJournal of Cataract & Refractive Surgery, 2014
- Severe Adverse Events after Cataract Surgery Among Medicare BeneficiariesOphthalmology, 2011
- OCULAR SIDE EFFECTS ASSOCIATED WITH PERIBULBAR INJECTIONS OF TRIAMCINOLONE ACETONIDE FOR DIABETIC MACULAR EDEMARetina, 2011
- Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgeryClinical Ophthalmology, 2010
- Outcomes of acute postoperative inflammation after cataract surgery.European Journal of Ophthalmology, 2007
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- A single intraoperative sub–Tenon's capsule triamcinolone acetonide injection for the treatment of post–cataract surgery inflammationOphthalmology, 2004
- Control of intra-ocular inflammation associated with cataract surgeryCurrent Opinion in Opthalmology, 2001
- Practical Problems with Eye-drops Among Elderly Ophthalmology OutpatientsAge and Ageing, 1992